APC and prostate cancer: However, mutations in β-catenin, APC, and other components of the destruction complex appear very rarely in prostate cancer cells [17–19], suggesting that other regulatory mechanisms underlie the activation of Wnt/β-catenin signaling in promoting prostate tumorigenesis.